Wegovy Users May Have 5 Times Risk of Vision Loss than Those on Ozempic

Why It Matters

If the dose‑dependent ocular risk is confirmed, clinicians must weigh weight‑loss benefits against potential vision loss, prompting updated safety guidance for high‑dose GLP‑1 therapies.

Key Takeaways

• Wegovy users face fivefold higher ION risk than Ozempic users
• Men on Wegovy have roughly three times risk versus women
• Higher semaglutide dose likely drives increased ocular adverse events
• Underlying metabolic comorbidities may confound observed risk differences
• No ION reports linked to oral Rybelsus in the dataset

Pulse Analysis

The rapid expansion of GLP‑1 receptor agonists for obesity and diabetes has brought unprecedented metabolic benefits, but it also raises safety questions beyond glycemic control. A recent pharmacovigilance analysis of more than 30 million reports identified a striking signal: Wegovy users experienced roughly five times the odds of ischemic optic neuropathy (ION) compared with Ozempic users, despite sharing the same active ingredient, semaglutide. The signal was absent for the oral formulation Rybelsus, suggesting that formulation and dosage may play critical roles in ocular outcomes.

Two patterns dominate the findings. First, the higher semaglutide dose in Wegovy (2.4 mg) versus Ozempic (2.0 mg) aligns with a dose‑dependent hypothesis, where greater receptor activation could impair optic nerve perfusion. Second, gender analysis revealed men faced about threefold higher ION risk than women, hinting at sex‑specific vascular susceptibilities or differential exposure. However, experts warn that the underlying metabolic burden of obesity, diabetes, and cardiovascular disease—prevalent among Wegovy recipients—could confound the association, making it unclear whether the drug or the patient profile drives the risk.

For clinicians, the emerging evidence mandates vigilant ophthalmic monitoring for patients initiating high‑dose semaglutide, especially men with existing vascular risk factors. Regulatory bodies may consider revising labeling to reflect potential ocular adverse events, while pharmaceutical developers are urged to explore alternative dosing strategies or delivery systems that mitigate this risk. Ultimately, prospective, controlled trials are essential to disentangle dose effects from comorbidities and to establish whether a causal link exists, ensuring that the therapeutic promise of GLP‑1 agonists does not come at the cost of vision loss.